abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

Posted by Brenda Bartman on Aug 28th, 2026

abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) was the recipient of a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 58,626 shares, a growth of 217.9% from the July 30th total of 18,442 shares. Based on an average trading volume of 149,213 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.2% of the shares of the company are short sold.

abrdn Life Sciences Investors Stock Down 2.6%

Shares of HQL traded down $0.57 during mid-day trading on Friday, hitting $20.98. 164,111 shares of the company traded hands, compared to its average volume of 129,602. The stock has a 50-day moving average price of $20.21 and a two-hundred day moving average price of $18.20. abrdn Life Sciences Investors has a 1 year low of $13.82 and a 1 year high of $22.67.

abrdn Life Sciences Investors Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Monday, August 24th will be given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 11.8%. The ex-dividend date of this dividend is Monday, August 24th.

Institutional Investors Weigh In On abrdn Life Sciences Investors

A number of hedge funds have recently added to or reduced their stakes in HQL. Wedbush Securities Inc. boosted its stake in shares of abrdn Life Sciences Investors by 50.6% in the 2nd quarter. Wedbush Securities Inc. now owns 15,960 shares of the company’s stock worth $319,000 after buying an additional 5,360 shares during the last quarter. KPP Advisory Services LLC increased its position in abrdn Life Sciences Investors by 2.7% during the second quarter. KPP Advisory Services LLC now owns 25,251 shares of the company’s stock valued at $505,000 after acquiring an additional 660 shares during the last quarter. 180 Wealth Advisors LLC increased its position in abrdn Life Sciences Investors by 2.2% during the second quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock valued at $3,058,000 after acquiring an additional 3,271 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in abrdn Life Sciences Investors by 17.6% in the first quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock valued at $387,000 after acquiring an additional 3,562 shares during the period. Finally, WNY Asset Management LLC bought a new position in abrdn Life Sciences Investors in the first quarter valued at about $239,000. 32.21% of the stock is currently owned by hedge funds and other institutional investors.

About abrdn Life Sciences Investors

(Get Free Report)

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.